Patents
Patents for C07D 401 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom (107,979)
02/2007
02/15/2007US20070037785 Novel dipeptidyl peptidase IV inhibitors used for functionally influencing different cells and treating immunological, infammatory, neuronal, and other diseases
02/15/2007US20070036854 Therapeutic applications of pro-apoptotic benzodiazepines
02/15/2007CA2618888A1 Acyltryptophanols for fertility control
02/15/2007CA2618112A1 Pyridone compound
02/15/2007CA2618103A1 Substituted triazole derivatives as oxytocin antagonists
02/15/2007CA2617557A1 Benzimidazole derivatives as sirtuin modulators
02/15/2007CA2617473A1 Acylguanidine derivative or salt thereof
02/15/2007CA2616977A1 Oxazolidinone-quinolone hybrids as antibacterial compounds
02/15/2007CA2616428A1 Pyrazine derivatives useful as adenosine receptor antagonists
02/15/2007CA2615695A1 Phenylpyridine derivatives, their manufacture and use as pharmaceutical agents
02/15/2007CA2612984A1 Antidiabetic oxazolidinediones and thiazolidinediones
02/15/2007CA2605481A1 Phosphonated fluoroquinolones, antibacterial analogs thereof, and methods for the prevention and treatment of bone and joint infections
02/14/2007EP1752455A2 Chemokine receptor binding heterocyclic compounds
02/14/2007EP1752452A1 Propane-1,3-dione derivative or its salt
02/14/2007EP1751152A2 Azinyl imidazoazine and azinyl carboxamide
02/14/2007EP1751149A1 Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
02/14/2007EP1751143A1 Pyrimidine derivatives for the treatment of abnormal cell growth
02/14/2007EP1751141A1 Novel pyridazinone derivatives as inhibitors of cdk2
02/14/2007EP1751140A1 Crystalline forms of a pyridinyl-sulfonamide and their use as endothelin receptor antagonists
02/14/2007EP1751139A2 Substituted pyrazolyl urea derivatives useful in the treatment of cancer
02/14/2007EP1751138A1 Indol-2-one derivatives for the treatment of central nervous disorders, gastrointestinal disorders and cardiovascular disorders
02/14/2007EP1751137A1 Diastereoselective synthesis process for the preparation of imidazole compounds
02/14/2007EP1751136A2 Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer
02/14/2007EP1751135A1 Process for producing piperidin-2,6-diones heterocyclically substituted at position 3
02/14/2007EP1751134A1 Pyridine derivatives of alkyl oxindoles as 5-ht7 receptor active agents
02/14/2007EP1751133A2 Compositions useful as inhibitors of rock and other protein kinases
02/14/2007EP1751132A1 2-substituted pyrimidines and their use as pesticides
02/14/2007EP1751131A1 Mtp inhibiting aryl piperidines or piperazines substituted with 5-membered heterocycles
02/14/2007EP1751130A2 Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands
02/14/2007EP1751124A2 Raf modulators and methods of use
02/14/2007EP1751118A1 Pyrimidines for use as plk inhibitors
02/14/2007EP1751116A2 Pyrimidine compounds and use thereof
02/14/2007EP1751115A1 Theramutein modulators
02/14/2007EP1751113A1 Urea antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
02/14/2007EP1751111A1 Substituted 1,2,3,4-tetrahydroisoquinoline derivatives
02/14/2007EP1751105A1 Piperazine derivatives of alkyl oxindoles
02/14/2007EP1751103A1 4-(5-(aminomethyl)-indole-1-ylmethyl)-benzamide derivatives and related compounds as opioid receptor antagonists for the treatment of obesity
02/14/2007EP1750706A1 Dual small molecule inhibitors of cancer and angiogenesis
02/14/2007EP1750704A2 Urea antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
02/14/2007EP1670782B1 Quinazoline derivatives
02/14/2007EP1532121B1 New use of pyrimidine - or triazine- 2-carbonitiles for treating diseases associated with cysteine protease activity and novel pyrimidine-2-carbonitile derivatives
02/14/2007EP1515963B1 A process for preparation of optically pure or optically enriched sulfoxide compounds, including amorphous esomeprazole and salts thereof
02/14/2007EP1444220B1 Compounds and method for the treatment of overactive bladder
02/14/2007EP1395554B1 Substituted carbazoles as inhibitors of spla2
02/14/2007EP1370552B1 Rho-kinase inhibitors
02/14/2007EP1345928B1 Pyrazole compounds useful as protein kinase inhibitors
02/14/2007EP1299378B1 Tetrahydropyridino or piperidino heterocyclic derivatives
02/14/2007EP1296961B1 1,4-diazepan-2,5-dione derivatives and their use as nk-1 receptor antagonists
02/14/2007EP0999256B1 Compounds for organic el element and organic el element
02/14/2007CN1914225A HCV NS-3 serine protease inhibitors
02/14/2007CN1914224A HCV NS-3 serine protease inhibitors
02/14/2007CN1914206A 7-phenylamino-4-quinolone-3-carboxylic acid derivatives, methods for production and use thereof as medicaments
02/14/2007CN1914196A 5- or 6-substituted benzimidazole derivatives as inhibitors of respiratiory syncytial virus replication
02/14/2007CN1914195A Substituted quinoline compounds
02/14/2007CN1914194A Therapeutic agent for vasospasm accompanying bypass operation
02/14/2007CN1914193A Heterocyclic anti-migraine agents
02/14/2007CN1914192A Methods for making 4-tetrazolyl-4-phenylpiperidine compounds
02/14/2007CN1914191A Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide
02/14/2007CN1914182A 喹唑啉衍生物 Quinazoline derivatives
02/14/2007CN1914179A Immobilized n-substituted tricyclic 3-aminopyrazoles for the identification of biomolecular targets
02/14/2007CN1914173A Quinolines useful in treating cardiovascular disease
02/14/2007CN1913895A Novel M3 muscarinic acetylcholine receptor antagonists
02/14/2007CN1913886A 杂环天冬氨酰蛋白酶抑制剂 Heterocyclic aspartyl protease inhibitors
02/14/2007CN1913884A Substituted benzazoles and methods of their use as inhibitors of RAF kinase
02/14/2007CN1911930A Chemokine receptor anagonists, methods and use therefor
02/14/2007CN1911927A Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and -1-oxoisoindolines and method of reducing tnf alpha levels
02/14/2007CN1911913A New neuropeptide YY5 receptor antagonists
02/14/2007CN1300116C 1H-indazole compound
02/14/2007CN1300114C Phenylpyridine carbonyl piperazine derivative
02/14/2007CN1300110C Hydroxamate derives useful as deacetylase inhibitors
02/14/2007CN1299677C 丙型肝炎病毒抑制剂 Hepatitis C virus inhibitors
02/13/2007US7176326 β-Lactams, methods for the preparation of taxanes, and sidechain-bearing taxanes
02/13/2007US7176322 Bone disorders; hyperparathyroidism; such as N-((1-ethyl-3-phenyl-1H-indol-5-yl)methyl)-1-phenylethanamine
02/13/2007US7176319 Process for substituted sulfoxides
02/13/2007US7176317 Anthraquinone, xanthene dyes
02/13/2007US7176316 Amino-piperidine derivatives
02/13/2007US7176315 Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3H-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1H-quinolin-2-one and salts thereof, useful in the treatment of cancer
02/13/2007US7176314 Inflammation modulators
02/13/2007US7176313 A oxoquinolines or a 4-oxo-1,8-naphthyridines or 7-oxo-7H-pyrido(1,2,3-de)(1,4)benzoxazine derivative for the treatment of tuberculosis, exhibits no cross resistance
02/13/2007US7176312 Kinase inhibitor scaffolds and methods for their preparation
02/13/2007US7176311 Process for preparing pharmaceutically active compounds
02/13/2007US7176306 Hydroxyalkyl cyclic diamine compound
02/13/2007US7176242 N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives
02/13/2007US7176229 Pyrrolidine antiinflammatory agents for rheumatoid arthritis, osteoarthritis; antiallergens for asthma, chronic bronchitis, allergic rhinitis, adult respiratory distress syndrome, chronic pulmonary inflammatory disease; reduce or eliminate adverse CNS side effects associated with prior PDE4 inhibitors
02/13/2007US7176227 Amine compounds and use thereof
02/13/2007US7176223 5-(3-Pyridylmethyl)imidazolidine-2,4-dione is subjected to a hydrolysis reaction, wherein the reaction is followed by a decarbamation reaction to obtain (3-pyridyl)alanine
02/13/2007US7176222 Contacting a base with an enantiomerically pure hydroxyl group containing compound, reacting the product with a nitro, fluoro-containing benzene compound, reducing the product to the corresponding amine
02/13/2007US7176220 Useful as an anti-HIV agent that particularly shows an anti-HIV action based on an integrase inhibitory activity; for treatment or prophylaxis of AIDS; for example, 6-(2,3-dichlorobenzyl)-1-(2-hydroxyethyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
02/13/2007US7176217 such as N-Hydroxy-2-[(4-methoxyphenyl)sulfonyl]-2-azabicyclo[2.2.1]heptane-3-carboxamide, used in cosmetics or drugs as gelatinase inhibitors, for preventing skin aging or wrinkling; preventing diseases due to abnormal metabolism of tissue matrices such as arthritis, ulcers, metastasis or tumors
02/13/2007US7176208 Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
02/13/2007US7176207 Anticoagulants; antithrombotic agents in the treatment and prevention of thrombosis
02/13/2007US7176206 Antibiotics
02/13/2007US7176205 Bi-pyridinyl derivatives as NK-1 antagonists
02/13/2007US7176204 Substituted carboxylic acid derivatives
02/13/2007US7176202 Such as 2-chloro-N-(1-hydroxy-cycloheptylmethyl)-5-[4-(2-hydroxy-3-methoxy-propyl)-3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl]-benzamide; purinergic receptors (P2x7 E); for treatment of interleukin-1 associated disorders, rheumatoid arthritis
02/13/2007US7176200 Derivatives of sulphonamides, their preparation and use as medicaments
02/13/2007US7176199 Useful as a preventive or/and a therapeutic agent for a disease in which alpha v beta 3 integrin is involved
02/13/2007US7176195 Treatment of nocturnal enuresis, nocturia, polyuria resulting from central diabetes insipidus, urinary incontinence or bleeding disorders such a hemophilia
02/13/2007US7175958 Electrophotographic photoconductor, process for forming an image, image forming apparatus and process cartridge for the same
02/13/2007US7175670 And an oxidation base; couplers such as N-(3,5-diaminopyrid-2-yl)pyrrolidine; strong, uniform dyeing results between the end and the root, resistant to external agents, capable of giving varied shades